Gilead to fork over $1.25B, pay 3% royalty on blockbuster Biktarvy in GSK patent settlementnews2022-02-01T21:28:44+00:00February 1st, 2022|Fierce Pharma|
Shkreli and Vyera settle for $28M in yet another Daraprim antitrust suitnews2022-02-01T19:39:47+00:00February 1st, 2022|Fierce Pharma|
GlaxoSmithKline’s HIV drug Cabenuva scores FDA nod for 2-month dosingnews2022-02-01T16:22:40+00:00February 1st, 2022|Fierce Pharma|
Novartis’ Sandoz reportedly the target of $25B buyout bid from Carlyle and Blackstonenews2022-02-01T16:09:57+00:00February 1st, 2022|Fierce Pharma|
Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovignews2022-02-01T15:36:19+00:00February 1st, 2022|Fierce Pharma|
Sherblom’s Comera inks SPAC merger to fund subcutaneous delivery programsnews2022-02-01T15:35:01+00:00February 1st, 2022|Fierce Pharma|
Purdue Pharma and Sackler family close to another big opioid settlement: reportsnews2022-02-01T14:20:57+00:00February 1st, 2022|Fierce Pharma|
Biogen’s Aduhelm support campaign backfires as CMS receives many more comments in favor of restrictive coverage: analystnews2022-02-01T14:20:07+00:00February 1st, 2022|Fierce Pharma|
Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analystnews2022-02-01T14:20:07+00:00February 1st, 2022|Fierce Pharma|
AstraZeneca runs first kidney disease focused Farxiga TV ad, getting in the homes of 37M people with this ‘silent disease’news2022-02-01T13:48:44+00:00February 1st, 2022|Fierce Pharma|
